about
Gene-gene Interaction Analyses for Atrial FibrillationTargeted sequencing in candidate genes for atrial fibrillation: the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Targeted Sequencing StudyHeart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins.Risk assessment for incident heart failure in individuals with atrial fibrillation.Digoxin in patients with permanent atrial fibrillation: data from the RACE II study.Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study.Telomere length and incident atrial fibrillation - data of the PREVEND cohort.Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study.Does intensity of rate control influence outcome in persistent atrial fibrillation? Data of the RACE study.Lone atrial fibrillation: does it exist?Relation of overweight and symptomatic atrial fibrillation: A case report.Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.Cardiovascular epigenetics: basic concepts and results from animal and human studies.Association between familial atrial fibrillation and risk of new-onset atrial fibrillation.Vitamin D status is not related to development of atrial fibrillation in the community.Atrial fibrillation: current knowledge and future directions in epidemiology and genomics.Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart StudyInsulin resistance and atrial fibrillation (from the Framingham Heart Study)White blood cell count and risk of incident atrial fibrillation (from the Framingham Heart Study)Meta-analysis identifies six new susceptibility loci for atrial fibrillationPlasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring StudySymptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities.Cluster Individuals Based on Phenotype and Determine the Risk for Atrial Fibrillation in the PREVEND and Framingham Heart Study Populations.Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation.Elevation of parathyroid hormone levels in atrial fibrillation.Clinical correlates of change in inflammatory biomarkers: The Framingham Heart Study.An update on the prognosis of patients with atrial fibrillation.Reciprocal relations between physical disability, subjective health, and atrial fibrillation: the Framingham Heart Study.Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study).Novel risk factors for atrial fibrillation: useful for risk prediction and clinical decision making?Who, when and how to rate control for atrial fibrillation.Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community.Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillationSerial galectin-3 and future cardiovascular disease in the general population.Heart failure highlights in 2011.Ventricular rate control of atrial fibrillation in heart failure.Heart failure highlights in 2012-2013.Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis.Atrial Fibrillation During Cardiac Resynchronization Therapy.Tailored treatment strategies: a new approach for modern management of atrial fibrillation.
P50
Q28596201-3402C67F-29D9-4FFC-88DF-2E90D036BABBQ28596201-4C492CCF-FF63-4B0D-9BAB-F522EF4C1761Q28658159-7A1F0B3E-5A10-4EAD-AB9A-E1F709050586Q30241128-32C0A0D9-C624-4CF6-B93A-4BEC578BD7A4Q30559212-44BBCC34-D67E-42AE-A67F-63B62A17F1EFQ30830811-B400B7BE-957B-4021-B0B3-8FD9FE3AD6ADQ31097352-C5D94DD8-BC0E-445D-9E65-723F7E3CF533Q31159385-539B1019-BDE5-40CA-8B1D-520F5F626359Q33224413-B6518EDC-F025-4C47-868E-F50F6FB20E17Q33512193-F9A68891-EF4F-42EB-BC9F-48EF349715FBQ33560948-696CBA6B-59E8-4EF9-8086-5D2A1B317F91Q33643412-A2791A79-4DE3-4A17-8C8B-2E4A7A3FA2A5Q34117950-195C7EF2-D5A0-45CD-B0EF-C296015D3D9EQ34537250-2E9E2929-ED1C-46D0-9BFD-E9ACE2858AE3Q34774717-758B8AA5-E77E-401C-96C4-D2FDF532C3C4Q35207725-97B0FFFE-E285-4C9A-A426-6EDF263E2A35Q35526930-B3660052-03CA-4462-8963-B4CF3C9FBF5DQ35602612-40A29393-3334-44DF-9544-8FA069CD8D1AQ35624021-E1411381-7C72-4245-8152-18777B3D7F15Q35722412-7479C2EF-EB40-44DE-B4D0-A1136B280BC0Q36004061-42118DB3-CF36-4D88-B2D1-E65BF1BDA6FBQ36032507-C36D05C3-78D5-4D66-8607-FE2B99B365DBQ36108848-53EF0B50-57AB-4256-9EC9-44171144A2E8Q36188656-32E85D3E-051B-45A8-8CC7-50154E2FF737Q36514049-F6451A04-242B-4B42-A6B5-75023CF01A66Q36820965-7908B59F-A605-4FF0-8421-4905A0A7FA0DQ36833592-C0D23287-DF16-43D1-A59E-BF3D05E2F266Q36919478-D70574C0-771C-4352-B9B5-DD18B1E7FFCDQ36981672-ACF3BF5B-708C-4110-BAC4-843A9A019534Q37007410-D0AE323F-305C-49DF-AE13-58B190DA035DQ37050536-968FD5E1-446F-4213-A479-5CDE8433017BQ37087180-004E5F97-D4CE-4F18-89CE-014CA043A1A2Q37328676-67BFB2AA-956B-4A51-B04A-B3416E56687DQ37449938-0C40887D-8D8E-45D7-BB9F-2F901FDA1C34Q37580709-13BBE46F-4D07-41D3-815E-71854746DA65Q38035177-CAC42B37-DCE2-47C3-A95D-8260119D520DQ38140237-FE38CFA9-6D54-4A7F-AC6A-8BD47A27A471Q38182010-8FE8A97C-4762-4EB0-A431-76A8B09DBCEBQ38195391-803145AF-EBE1-4B4C-A9B0-BEA3F41D424CQ38644134-9B158817-E6B0-488F-91A8-04BE8CB7AD0A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michiel Rienstra
@ast
Michiel Rienstra
@en
Michiel Rienstra
@es
Michiel Rienstra
@nl
Michiel Rienstra
@sl
type
label
Michiel Rienstra
@ast
Michiel Rienstra
@en
Michiel Rienstra
@es
Michiel Rienstra
@nl
Michiel Rienstra
@sl
prefLabel
Michiel Rienstra
@ast
Michiel Rienstra
@en
Michiel Rienstra
@es
Michiel Rienstra
@nl
Michiel Rienstra
@sl
P106
P1153
8858826600
P21
P31
P496
0000-0002-2581-070X